Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. Financials
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 112120139144--
Entreprise Value (EV)1 -20,261,1122160204200
P/E ratio -2,93x-1,92x-1,78x-1,33x-1,92x21,2x
Yield ------
Capitalization / Revenue 25,2x22,7x37,4x14,7x3,71x1,17x
EV / Revenue -4,55x11,6x32,8x16,4x5,25x1,62x
EV / EBITDA 0,47x-1,02x-1,91x-2,28x-4,15x16,4x
Price to Book 0,77x1,40x4,93x-6,34x-2,05x-3,71x
Nbr of stocks (in thousands) 17 93817 93819 56227 727--
Reference price (EUR) 6,256,707,115,205,205,20
Announcement Date 03/11/201903/16/202003/08/2021---
1 EUR in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 4,455,283,729,7938,9123
EBITDA1 -42,8-59,9-63,8-70,4-49,112,2
Operating profit (EBIT)1 -43,6-64,1-68,8-66,0-41,836,3
Operating Margin -981%-1 213%-1 851%-675%-108%29,5%
Pre-Tax Profit (EBT)1 -38,2-62,7-73,3-58,5-49,839,0
Net income1 -38,2-62,7-73,3-65,1-43,733,0
Net margin -860%-1 186%-1 971%-665%-112%26,8%
EPS2 -2,13-3,49-3,99-3,90-2,720,25
Dividend per Share ------
Announcement Date 03/11/201903/16/202003/08/2021---
1 EUR in Million
2 EUR
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q3 2020 Q4 2020 S2 2021 Q1 2021 Q2 2021 S1
Net sales1 1,040,831,871,931,251,10
EBITDA ---31,0---31,0
Operating profit (EBIT)1 -16,1-17,3-33,5-16,6-14,2-33,7
Operating Margin -1 549%-2 093%-1 790%-862%-1 139%-3 064%
Pre-Tax Profit (EBT)1 -18,6-19,7-38,3-17,4-13,3-34,6
Net income1 -18,6-19,7-38,3-17,4-13,3-34,6
Net margin -1 786%-2 385%-2 051%-904%-1 067%-3 145%
EPS ---2,04---1,70
Dividend per Share ------
Announcement Date 11/05/202003/08/202103/08/2021---
1 EUR in Million
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt1 ---16,159,855,8
Net Cash position1 13259,117,0---
Leverage (Debt / EBITDA) 3,09x0,99x0,27x-0,23x-1,22x4,57x
Free Cash Flow1 -53,5-63,4-52,9-75,1-43,84,00
ROE (Net Profit / Equities) -23,4%-54,2%-131%---
Shareholders' equity1 16411656,0---
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 8,124,771,44-0,82-2,54-1,40
Cash Flow per Share -2,19-2,41----
Capex1 14,220,11,141,301,802,90
Capex / Sales 320%381%30,6%13,3%4,63%2,35%
Announcement Date 03/11/201903/16/202003/08/2021---
1 EUR in Million
2 EUR
Key data
Capitalization (EUR) 144 178 044
Capitalization (USD) 169 242 921
Net sales (EUR) 3 718 000
Net sales (USD) 4 363 928
Number of employees 206
Sales / Employee (EUR) 18 049
Sales / Employee (USD) 21 184
Free-Float 88,9%
Free-Float capitalization (EUR) 128 204 395
Free-Float capitalization (USD) 150 492 306
Avg. Exchange 20 sessions (EUR) 1 812 027
Avg. Exchange 20 sessions (USD) 2 126 831
Average Daily Capital Traded 1,26%
EPS & Dividend